These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18802977)

  • 21. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
    Wilkins E
    J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
    [No Abstract]   [Full Text] [Related]  

  • 22. Ritonavir manufacturing problems.
    Highleyman L
    BETA; 1998 Oct; ():4. PubMed ID: 11365991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A light meal at the same time is enough. Advantages of natural enhancement of nelfinavir].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():57. PubMed ID: 15011592
    [No Abstract]   [Full Text] [Related]  

  • 24. Soft-gel Norvir.
    AIDS Patient Care STDS; 1999 Jul; 13(7):437. PubMed ID: 10870598
    [No Abstract]   [Full Text] [Related]  

  • 25. Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
    DeGoey DA; Grampovnik DJ; Flosi WJ; Marsh KC; Wang XC; Klein LL; McDaniel KF; Liu Y; Long MA; Kati WM; Molla A; Kempf DJ
    J Med Chem; 2009 May; 52(9):2964-70. PubMed ID: 19348416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Women and Norvir.
    Posit Aware; 2000; 11(1):25. PubMed ID: 11366346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of improved oral bioavailability of ritonavir nanosuspension.
    Karakucuk A; Teksin ZS; Eroglu H; Celebi N
    Eur J Pharm Sci; 2019 Apr; 131():153-158. PubMed ID: 30790704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
    van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
    Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Less dose burden for Viracept.
    AIDS Patient Care STDS; 2003 Jul; 17(7):365. PubMed ID: 12952738
    [No Abstract]   [Full Text] [Related]  

  • 31. Ritonavir oral solution: still graduated in ml in the EU.
    Prescrire Int; 2012 Oct; 21(131):235. PubMed ID: 23185845
    [No Abstract]   [Full Text] [Related]  

  • 32. Improved tolerability of ritonavir derived from pharmacokinetic principles.
    Merry C; Barry M; Gibbons S; Mulcahy F; Back D
    Br J Clin Pharmacol; 1996 Dec; 42(6):787. PubMed ID: 8971438
    [No Abstract]   [Full Text] [Related]  

  • 33. Reformulated ritonavir.
    AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743543
    [No Abstract]   [Full Text] [Related]  

  • 34. Development and in vivo evaluation of functionalized ritonavir proliposomes for lymphatic targeting.
    Ahammed V; Narayan R; Paul J; Nayak Y; Roy B; Shavi GV; Nayak UY
    Life Sci; 2017 Aug; 183():11-20. PubMed ID: 28647214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects.
    Yadav M; Rao R; Kurani H; Singhal P; Goswami S; Shrivastav PS
    J Pharm Biomed Anal; 2009 May; 49(4):1115-22. PubMed ID: 19282124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
    L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
    AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
    AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
    [No Abstract]   [Full Text] [Related]  

  • 39. Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data.
    Rossi RC; Dias CL; Donato EM; Martins LA; Bergold AM; Fröehlich PE
    Int J Pharm; 2007 Jun; 338(1-2):119-24. PubMed ID: 17343999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
    Bénard A; Damond F; Campa P; Peytavin G; Descamps D; Lascoux-Combes C; Taieb A; Simon F; Autran B; Brun-Vézinet F; Chêne G; Matheron S;
    AIDS; 2009 Jun; 23(9):1171-3. PubMed ID: 19349850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.